| scholarly article | Q13442814 |
| P50 | author | Mark Borris Docdoc Aldonza | Q42369203 |
| Malona V Alinsug | Q59692869 | ||
| Sang Kook Lee | Q87632263 | ||
| P2093 | author name string | Ji-Young Hong | |
| Jayoung Song | |||
| P2860 | cites work | Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance | Q24294967 |
| Microtubule-binding agents: a dynamic field of cancer therapeutics | Q27690249 | ||
| Multidrug resistance in cancer: role of ATP-dependent transporters | Q28208049 | ||
| Protein degradation by the ubiquitin-proteasome pathway in normal and disease states | Q28243121 | ||
| Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors? | Q28250433 | ||
| Multiple molecular mechanisms for multidrug resistance transporters | Q28297705 | ||
| Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer | Q28475229 | ||
| Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein | Q28481246 | ||
| A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation | Q28512163 | ||
| Agrin induced morphological and structural changes in growth cones of cultured hippocampal neurons | Q28565033 | ||
| The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs | Q29615910 | ||
| An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer | Q29616732 | ||
| FoxO mediates APP-induced AICD-dependent cell death | Q30580094 | ||
| DNA methylation patterns at relapse in adult acute lymphocytic leukemia | Q33183805 | ||
| Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents | Q33630855 | ||
| FOXOs, cancer and regulation of apoptosis | Q33642512 | ||
| Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells | Q33664289 | ||
| Mechanisms of Taxol resistance related to microtubules. | Q33688044 | ||
| Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. | Q33721192 | ||
| Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer | Q33775726 | ||
| Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer | Q33892868 | ||
| Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. | Q34032640 | ||
| Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS | Q34039745 | ||
| How Taxol/paclitaxel kills cancer cells. | Q34166802 | ||
| Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation | Q34324051 | ||
| Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance | Q34375087 | ||
| Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment | Q34602948 | ||
| MDR1 transporter protects against paraquat-induced toxicity in human and mouse proximal tubule cells. | Q34736271 | ||
| Insights into the mechanism of microtubule stabilization by Taxol. | Q34771867 | ||
| Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells | Q35670917 | ||
| Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells | Q35723911 | ||
| FoxO limits microtubule stability and is itself negatively regulated by microtubule disruption | Q35744534 | ||
| Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer | Q35832938 | ||
| Therapy-induced tumour secretomes promote resistance and tumour progression | Q35867131 | ||
| Altered TUBB3 expression contributes to the epothilone response of mitotic cells. | Q36557893 | ||
| Bcl-2—Enhanced Efficacy of Microtubule-Targeting Chemotherapy through Bim Overexpression: Implications for Cancer Treatment | Q36567569 | ||
| The proteasome as a potential target for novel anticancer drugs and chemosensitizers | Q36695969 | ||
| A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin | Q36696272 | ||
| Autoregulated changes in stability of polyribosome-bound beta-tubulin mRNAs are specified by the first 13 translated nucleotides | Q36785250 | ||
| Microtubule-associated proteins as targets in cancer chemotherapy | Q36823252 | ||
| Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? | Q37073084 | ||
| PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells. | Q37073648 | ||
| Many forks in the path: cycling with FoxO. | Q37129798 | ||
| Beyond taxol: microtubule-based treatment of disease and injury of the nervous system | Q37200301 | ||
| Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells | Q37214346 | ||
| Melanoma and the tumor microenvironment | Q37244724 | ||
| Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer. | Q37428849 | ||
| Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin | Q37570220 | ||
| FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. | Q37598769 | ||
| Forkhead box proteins: tuning forks for transcriptional harmony. | Q38116309 | ||
| Drug resistance-related miRNAs in hepatocellular cancer | Q38185706 | ||
| Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance. | Q38270775 | ||
| Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells | Q38292631 | ||
| Antitumor activity of phenanthroindolizidine alkaloids is associated with negative regulation of Met endosomal signaling in renal cancer cells. | Q38888349 | ||
| Stanniocalcin-2 (STC2): A potential lung cancer biomarker promotes lung cancer metastasis and progression. | Q38933254 | ||
| Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. | Q38971290 | ||
| miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. | Q39119238 | ||
| Magnolol inhibits angiogenesis by regulating ROS-mediated apoptosis and the PI3K/AKT/mTOR signaling pathway in mES/EB-derived endothelial-like cells | Q39147177 | ||
| The PI3K/AKT signaling pathway controls the quiescence of the low-Rhodamine123-retention cell compartment enriched for melanoma stem cell activity. | Q39203640 | ||
| Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer | Q39236264 | ||
| β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer | Q39345531 | ||
| Transcriptional and post-transcriptional regulation of βIII-tubulin protein expression in relation with cell cycle-dependent regulation of tumor cells | Q39429859 | ||
| Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin | Q39435517 | ||
| Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin. | Q39731067 | ||
| The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model. | Q40099844 | ||
| Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules | Q40310864 | ||
| Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. | Q40333129 | ||
| Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel | Q40411538 | ||
| Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure | Q40574551 | ||
| Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. | Q40662314 | ||
| Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway | Q41833207 | ||
| Cell biology: Tubulin acetylation and cell motility | Q42806332 | ||
| The roles of beta-tubulin mutations and isotype expression in acquired drug resistance | Q43137052 | ||
| Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. | Q43812462 | ||
| Effect of promoter methylation of multidrug resistance 1 (MDR1) gene in gastric carcinogenesis | Q44555572 | ||
| Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. | Q45213258 | ||
| Role of PTEN protein in multidrug resistance of prostate cancer cells | Q46430488 | ||
| Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells | Q46662807 | ||
| MicroTUB(B3)ules and brain development | Q48340432 | ||
| Foxo3a is essential for maintenance of the hematopoietic stem cell pool. | Q51960990 | ||
| Investigation of Paclitaxel Resistant R306C Mutation in β-Tubulin—A Computational Approach | Q52962430 | ||
| Resist or die: FOXO transcription factors determine the cellular response to chemotherapy | Q53446661 | ||
| Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a | Q80444906 | ||
| Tumor Endothelial Cells Acquire Drug Resistance by MDR1 Up-Regulation via VEGF Signaling in Tumor Microenvironment | Q83244416 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 34395-34419 | |
| P577 | publication date | 2016-06-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation | |
| P478 | volume | 7 |
| Q41634218 | ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine |
| Q48522177 | Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway |
| Q52677630 | NOVA1 acts as an oncogene in melanoma via regulating FOXO3a expression. |
| Q89186003 | Optimization Of Cancer Treatment Through Overcoming Drug Resistance |
| Q37624466 | Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation |
| Q38806888 | Paraoxonase-1 (PON1) induces metastatic potential and apoptosis escape via its antioxidative function in lung cancer cells. |
| Q49164320 | Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer. |
| Q89824200 | Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms |
| Q93188493 | RILPL2 regulates breast cancer proliferation, metastasis, and chemoresistance via the TUBB3/PTEN pathway |
| Q46316359 | Structure Identification and In Vitro Anticancer Activity of Lathyrol-3-phenylacetate-5,15-diacetate |
| Q52602328 | Substituents at the C3' and C3'N positions are critical for taxanes to overcome acquired resistance of cancer cells to paclitaxel |
| Q39152624 | The role of exosomes and miRNAs in drug-resistance of cancer cells. |
Search more.